This study aims to prospectively assess the impact of distant effects from breast radiation on ovarian reserve. We will determine ovarian reserve through blood measurements of Anti-Müllerian Hormone (AMH), a relatively new and reliable serum biomarker of ovarian reserve that has already been incorporated into the standard practice of reproductive endocrinology and infertility.
You may be eligible if you are: female (or assigned female at birth), aged 18-45, and diagnosed with in-situ breast cancer or stage 1 breast cancer
Mitchell Rosen, MD
Principal Investigator
